Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 3/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | KIF11 | P52732 | 2/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | USP1 | O94782 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | UBE2N | P61088 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | SDHB | P21912 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18865485 | 0.95 | CYP11B2 (0.44) | CYP11B2CYP11B1KDM1AKIF11PDPK1 | |
| SCHEMBL31254896 | 0.89 | TGFBR1 (0.41) | CYP11B2CYP11B1KDM1AKIF11PDPK1 | |
| SCHEMBL18886504 | 0.86 | KDM1A (0.42) | CYP11B2CYP11B1KDM1AKIF11PDPK1 | |
| SCHEMBL29864349 | 0.86 | USP1 (0.41) | CYP11B2CYP11B1KDM1AKIF11PDPK1 | |
| Hydrochloric Acid SCHEMBL18865617 | 0.85 | KDM1A (0.42) | CYP11B2CYP11B1KDM1AKIF11PDPK1 | |
| SCHEMBL29864259 | 0.85 | USP1 (0.41) | CYP11B2CYP11B1KDM1AKIF11USP1 | |
| SCHEMBL31254602 | 0.81 | KIF11 (0.38) | CYP11B2CYP11B1KDM1AKIF11PDPK1 | |
| SCHEMBL18865631 | 0.80 | TGFBR1 (0.37) | CYP11B2CYP11B1KDM1AALDH1A1PTGS2 | |
| SCHEMBL31155892 | 0.80 | USP1 (0.41) | KIF11USP1PTGS2 | |
| SCHEMBL25975796 | 0.80 | USP1 (0.41) | USP1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059689-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | MEDIVIR AB (SE) | 2024-02-22 | — | — | US | disclosed |
| EP-4308566-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | Tango Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-117425656-A | Purine derivatives as anticancer agents | 探戈医药股份有限公司 | 2024-01-19 | — | — | CN | disclosed |
| WO-2023148643-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | WO | disclosed |
| WO-2022197892-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | TANGO THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059689-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | RRM2, TYMP, PNP | CYP11B2 1801/4885CYP11B1 1208/4885KDM1A 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.